Today, the President & CEO of Palatin Technologies (PTN), Carl Spana, bought shares of PTN for $15.6K.
In addition to Carl Spana, 2 other PTN executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
PTN’s market cap is $163M and the company has a P/E ratio of 20.86. Currently, Palatin Technologies has an average volume of 3.94M.
Starting in November 2017, PTN received 9 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Palatin Technologies, Inc. is a biopharmaceutical company which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
